{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T09:10:42Z","timestamp":1791882642721,"version":"4.3.4"},"reference-count":124,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.jhep.2021.10.011","type":"journal-article","created":{"date-parts":[[2021,10,22]],"date-time":"2021-10-22T07:54:04Z","timestamp":1634889244000},"page":"435-445","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":50,"title":["Long-term sequelae of drug-induced liver injury"],"prefix":"10.1016","volume":"76","author":[{"given":"Einar S.","family":"Bj\u00f6rnsson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raul J.","family":"Andrade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2021.10.011_bib1","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/j.jhep.2019.02.014","article-title":"EASL clinical practice guidelines: drug-induced liver injury","volume":"70","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.10.011_bib2","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1056\/NEJMra1816149","article-title":"Drug induced liver injury: types and phenotypes","volume":"381","author":"Hoofnagle","year":"2019","journal-title":"N\u00a0Eng J Med"},{"key":"10.1016\/j.jhep.2021.10.011_bib3","first-page":"514","article-title":"Chronic liver injury induced by drugs and toxins","volume":"19","author":"Ortega-Alonso","year":"2018","journal-title":"J\u00a0Dig Dis"},{"key":"10.1016\/j.jhep.2021.10.011_bib4","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1055\/s-0039-1685519","article-title":"Assessment of serious acute and chronic idiosyncratic drug-induced liver injury in clinical practice","volume":"39","author":"Bessone","year":"2019","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.jhep.2021.10.011_bib5","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1136\/gut.44.5.731","article-title":"The natural history of histologically proved drug induced liver disease","volume":"44","author":"Aithal","year":"1999","journal-title":"Gut"},{"issue":"6","key":"10.1016\/j.jhep.2021.10.011_bib6","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1002\/hep.21424","article-title":"Outcome of acute idiosyncratic drug-induced liver injury: long-term follow-up in a hepatotoxicity registry","volume":"44","author":"Andrade","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2021.10.011_bib7","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/j.1365-2036.2007.03355.x","article-title":"Long-term follow-up in patients with mild to moderate drug-induced liver injury","volume":"26","author":"Bj\u00f6rnsson","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2021.10.011_bib8","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1053\/j.gastro.2008.09.011","article-title":"Causes, clinical features, and outcomes from a prospective study of drug induced liver injury in the United States","volume":"135","author":"Chalasani","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2021.10.011_bib9","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.jhep.2008.10.021","article-title":"The long-term follow-up after idiosyncratic drug-induced liver injury with jaundice","volume":"50","author":"Bj\u00f6rnsson","year":"2009","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.10.011_bib10","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1053\/j.gastro.2014.03.045","article-title":"Idiosyncratic drug-induced liver injury is associated with substantial morbidity and mortality within 6 months from onset","volume":"147","author":"Fontana","year":"2014","journal-title":"Gastroenterology"},{"issue":"10","key":"10.1016\/j.jhep.2021.10.011_bib11","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1038\/ajg.2015.283","article-title":"Persistent liver biochemistry abnormalities are more common in older patients and those with cholestatic drug induced liver injury","volume":"110","author":"Fontana","year":"2015","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"10.1016\/j.jhep.2021.10.011_bib12","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.jhep.2016.05.003","article-title":"Definition and risk factors for chronicity following acute idiosyncratic drug-induced liver injury","volume":"65","author":"Medina-Caliz","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.10.011_bib13","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1053\/j.gastro.2015.03.006","article-title":"Features and outcomes of 899 patients with drug-induced liver injury: the DILIN prospective study","volume":"148","author":"Chalasani","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2021.10.011_bib14","first-page":"197","article-title":"Incidence and sequelae of liver injury among children treated for solid tumors: analysis of a large single-center prospective cohort","volume":"71","author":"Cardenas","year":"2020","journal-title":"JPGN"},{"issue":"Suppl 1","key":"10.1016\/j.jhep.2021.10.011_bib15","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0168-8278(97)82329-X","article-title":"Plasma membrane cytochromes P450 as neoantigens and autoimmune targets in drug-induced hepatitis","volume":"26","author":"Robin","year":"1997","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.10.011_bib16","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1111\/j.1749-6632.1993.tb35929.x","article-title":"Autoantibodies against cytochromes P-450 in drug-induced autoimmune hepatitis","volume":"685","author":"Beaune","year":"1993","journal-title":"Ann N Y Acad Sci"},{"issue":"Suppl 1","key":"10.1016\/j.jhep.2021.10.011_bib17","first-page":"S74","article-title":"The influence of the acetylator phenotype for the clinical use of dihydralazine","volume":"23","author":"Siegmund","year":"1985","journal-title":"Int J Clin Pharmacol Ther Toxicol"},{"key":"10.1016\/j.jhep.2021.10.011_bib18","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/S0026-895X(25)10602-0","article-title":"Interactions of dihydralazine with cytochromes P4501A: a possible explanation for the appearance of anti-cytochrome P4501A2 autoantibodies","volume":"45","author":"Bourdi","year":"1994","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.jhep.2021.10.011_bib19","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.cgh.2016.05.043","article-title":"Features of autoimmune hepatitis in patients with drug- induced liver injury","volume":"15","author":"de Boer","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2021.10.011_bib20","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1002\/hep.1840080327","article-title":"Hepatic injury associated with the use of nitrofurans: a clinicopathological study of 52 reported cases","volume":"8","author":"Stricker","year":"1988","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2021.10.011_bib21","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1136\/bmj.312.7024.169","article-title":"Minocycline induced autoimmune hepatitis and systemic lupus erythematosus-like syndrome","volume":"312","author":"Gough","year":"1996","journal-title":"BMJ"},{"key":"10.1016\/j.jhep.2021.10.011_bib22","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1002\/hep.23588","article-title":"Drug-induced autoimmune hepatitis: clinical characteristics and prognosis","volume":"51","author":"Bj\u00f6rnsson","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2021.10.011_bib23","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.cgh.2014.07.062","article-title":"The risk of drug-induced liver injury from Tumor Necrosis Factor (TNF)-alpha-antagonists","volume":"13","author":"Bj\u00f6rnsson","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2021.10.011_bib24","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1016\/j.cgh.2017.05.027","article-title":"Drug-induced autoimmune hepatitis: response to corticosteroids and lack of relapse after cessation of steroids","volume":"15","author":"Bj\u00f6rnsson","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2021.10.011_bib25","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1080\/003655202761020687","article-title":"Drug-induced liver injury associated with antinuclear antibodies","volume":"37","author":"Ohmoto","year":"2002","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.jhep.2021.10.011_bib26","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1002\/hep.24513","article-title":"Seven cases of autoimmune hepatitis that developed after drug-induced liver injury","volume":"54","author":"Sugimoto","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2021.10.011_bib27","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.jhep.2010.12.041","article-title":"Recurrent drug-induced liver injury (DILI) with different drugs in the Spanish Registry: the dilemma of the relationship to autoimmune hepatitis","volume":"55","author":"Lucena","year":"2011","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.10.011_bib28","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1097\/00004836-198612000-00022","article-title":"Sclerosing cholangitis from intraarterial floxuridine","volume":"8","author":"Dikengil","year":"1986","journal-title":"J\u00a0Clin Gastroenterol"},{"key":"10.1016\/j.jhep.2021.10.011_bib29","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/hep.1840090209","article-title":"Floxuridine-induced sclerosing cholangitis: an ischemic cholangiopathy?","volume":"9","author":"Ludwig","year":"1989","journal-title":"Hepatology (Baltimore, Md)"},{"key":"10.1016\/j.jhep.2021.10.011_bib30","first-page":"1302","article-title":"Extrahepatic biliary stenoses after hepatic arterial infusion (HAI) of floxuridine (FUdR) for liver metastases from colorectal cancer","volume":"48","author":"Aldrighetti","year":"2001","journal-title":"Hepato-Gastroenterology"},{"key":"10.1016\/j.jhep.2021.10.011_bib31","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.crad.2005.01.006","article-title":"Bile duct complications of hepatic arterial infusion chemotherapy evaluated by helical CT","volume":"60","author":"Phongkitkarun","year":"2005","journal-title":"Clin Radiol"},{"key":"10.1016\/j.jhep.2021.10.011_bib32","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.crad.2006.02.013","article-title":"Chemotherapy-induced sclerosing cholangitis","volume":"61","author":"Sandrasegaran","year":"2006","journal-title":"Clin Radiol"},{"key":"10.1016\/j.jhep.2021.10.011_bib33","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/BF00571690","article-title":"Methimazole-induced cholestatic liver injury, mimicking sclerosing cholangitis","volume":"381","author":"Schwab","year":"1996","journal-title":"Langenbecks Archiv fur Chirurgie"},{"key":"10.1016\/j.jhep.2021.10.011_bib34","doi-asserted-by":"crossref","first-page":"3814","DOI":"10.1007\/s10620-015-3914-3","article-title":"Docetaxel induced sclerosing cholangitis","volume":"60","author":"Horsley-Silva","year":"2015","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jhep.2021.10.011_bib35","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1038\/ajg.2010.485","article-title":"Ketamine-induced cholangiopathy: a case report","volume":"106","author":"Seto","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2021.10.011_bib36","first-page":"e52","article-title":"Cholestasis and biliary dilatation associated with chronic ketamine abuse: a case series","volume":"52","author":"Lo","year":"2011","journal-title":"Singapore Med J"},{"key":"10.1016\/j.jhep.2021.10.011_bib37","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1002\/hep.26459","article-title":"Ketamine abuse, biliary tract disease, and secondary sclerosing cholangitis","volume":"58","author":"Turkish","year":"2013","journal-title":"Hepatology (Baltimore, Md)"},{"key":"10.1016\/j.jhep.2021.10.011_bib38","doi-asserted-by":"crossref","DOI":"10.12809\/hkmj133796","article-title":"Ketamine-induced cholangiopathy","volume":"20","author":"Lui","year":"2014","journal-title":"Hong Kong Med J"},{"key":"10.1016\/j.jhep.2021.10.011_bib39","article-title":"Ketamine-induced sclerosing cholangitis (KISC) in a critically ill patient with COVID-19","author":"Knooihuizen","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2021.10.011_bib40","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.dld.2015.03.002","article-title":"Secondary sclerosing cholangitis in patients with drug-induced liver injury","volume":"47","author":"Gudnason","year":"2015","journal-title":"Dig Liv Dis"},{"key":"10.1016\/j.jhep.2021.10.011_bib41","article-title":"Sclerosing cholangitis like changes on magnetic resonance cholangiography in patients with drug induced liver injury","author":"Ahmad","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2021.10.011_bib42","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1093\/annonc\/mdq013","article-title":"Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study","volume":"21","author":"O'Day","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jhep.2021.10.011_bib43","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhep.2021.10.011_bib44","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1002\/hep4.1465","article-title":"Biologic and checkpoint inhibitor-induced liver injury: a systematic literature review","volume":"4","author":"Shah","year":"2020","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jhep.2021.10.011_bib45","doi-asserted-by":"crossref","first-page":"251","DOI":"10.14309\/ajg.0000000000000398","article-title":"Clinical characteristics and adverse impact of hepatotoxicity due to immune checkpoint inhibitors","volume":"115","author":"Miller","year":"2020","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2021.10.011_bib46","article-title":"Severe steroid-resistant anti-PD1 T-cell checkpoint inhibitor-induced hepatotoxicity driven by biliary injury","volume":"2","author":"Doherty","year":"2017","journal-title":"ESMO"},{"key":"10.1016\/j.jhep.2021.10.011_bib47","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1093\/annonc\/mdw649","article-title":"Nivolumab-induced cholangitic liver disease: a novel form of serious liver injury","volume":"28","author":"Gelsomino","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jhep.2021.10.011_bib48","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s10637-017-0453-0","article-title":"Imaging and clinicopathological features of nivolumab-related cholangitis in patients with non-small cell lung cancer","volume":"35","author":"Kawakami","year":"2017","journal-title":"Invest N Drugs"},{"key":"10.1016\/j.jhep.2021.10.011_bib49","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1007\/s10637-017-0484-6","article-title":"A\u00a0case of nivolumab-related cholangitis and literature review: how to look for the right tools for a correct diagnosis of this rare immune-related adverse event","volume":"36","author":"Gelsomino","year":"2018","journal-title":"Invest N Drugs"},{"key":"10.1016\/j.jhep.2021.10.011_bib50","doi-asserted-by":"crossref","first-page":"e34","DOI":"10.1016\/j.jtho.2017.10.007","article-title":"Late-onset cholecystitis with cholangitis after avelumab treatment in non-small cell lung cancer","volume":"13","author":"Cho","year":"2018","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jhep.2021.10.011_bib51","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1111\/jgh.14136","article-title":"Hepatobiliary and pancreatic: nivolumab-related cholangiopathy","volume":"33","author":"Hamoir","year":"2018","journal-title":"J\u00a0Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2021.10.011_bib52","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s00262-017-2062-3","article-title":"Bile duct obstruction in a patient treated with nivolumab as second-line chemotherapy for advanced non-small-cell lung cancer: a case report","volume":"67","author":"Kashima","year":"2018","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.jhep.2021.10.011_bib53","doi-asserted-by":"crossref","first-page":"E259","DOI":"10.1055\/a-0640-2392","article-title":"Peroral cholangioscopy of nivolumab-related (induced) ulcerative cholangitis in a patient with non-small cell lung cancer","volume":"50","author":"Kuraoka","year":"2018","journal-title":"Endoscopy"},{"key":"10.1016\/j.jhep.2021.10.011_bib54","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1002\/hep.30189","article-title":"Antiprogrammed cell death-1 immunotherapy-related secondary sclerosing cholangitis","volume":"69","author":"Ogawa","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2021.10.011_bib55","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ejca.2018.11.021","article-title":"Development of mild drug-induced sclerosing cholangitis after discontinuation of nivolumab","volume":"107","author":"Noda-Narita","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jhep.2021.10.011_bib56","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.2169\/internalmedicine.1981-18","article-title":"Efficacy and safety of chemotherapy following anti-PD1 antibody therapy for gastric cancer: a case of sclerosing cholangitis","volume":"58","author":"Kono","year":"2019","journal-title":"Intern Med"},{"key":"10.1016\/j.jhep.2021.10.011_bib57","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.2169\/internalmedicine.2330-18","article-title":"Successful treatment of nivolumab-related cholangitis with prednisolone: a case report and review of the literature","volume":"58","author":"Sawada","year":"2019","journal-title":"Intern Med"},{"key":"10.1016\/j.jhep.2021.10.011_bib58","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1111\/his.14000","article-title":"Immune-related adverse reactions in the hepatobiliary system: second-generation check-point inhibitors highlight diverse histological changes","volume":"76","author":"Zen","year":"2020","journal-title":"Histopathology"},{"key":"10.1016\/j.jhep.2021.10.011_bib59","doi-asserted-by":"crossref","first-page":"e000487","DOI":"10.1136\/bmjgast-2020-000487","article-title":"Case of nivolumab-induced sclerosing cholangitis: lessons from long-term follow-up","volume":"7","author":"McClure","year":"2020","journal-title":"BMJ Open Gastro"},{"key":"10.1016\/j.jhep.2021.10.011_bib60","first-page":"100270","article-title":"Atezolizumab-induced Sclerosing Cholangitis in a patient with lung cancer: a case report","volume":"26","author":"Nabeshima","year":"2021","journal-title":"Cancer Treat Res Commun"},{"key":"10.1016\/j.jhep.2021.10.011_bib61","doi-asserted-by":"crossref","first-page":"353","DOI":"10.3748\/wjg.v26.i3.353","article-title":"Programmed cell death-1 inhibitor-related sclerosing cholangitis: a systematic review","volume":"26","author":"Onoyama","year":"2020","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jhep.2021.10.011_bib62","doi-asserted-by":"crossref","first-page":"193","DOI":"10.4065\/73.3.285","article-title":"Idiopathic adulthood ductopenia: an update","volume":"73","author":"Ludwig","year":"1998","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.jhep.2021.10.011_bib63","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1002\/hep.1840150212","article-title":"Drug-induced prolonged cholestasis in adults: a histological semiquantitative study demonstrating progressive ductopenia","volume":"15","author":"Degott","year":"1992","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2021.10.011_bib64","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0168-8278(88)80482-3","article-title":"Idiopathic adulthood ductopenia. A cause of chronic cholestatic liver disease and biliary cirrhosis","volume":"17","author":"Ludwig","year":"1988","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.10.011_bib65","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0168-8278(97)82330-6","article-title":"Vanishing bile duct syndrome in drug-induced liver disease","volume":"26","author":"Desmet","year":"1997","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.10.011_bib66","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/0168-8278(92)90029-O","article-title":"Liver damage from flucloxacillin, cloxacillin and dicloxacillin","volume":"15","author":"Olsson","year":"1992","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.10.011_bib67","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/0016-5085(92)90780-3","article-title":"Carbamazepine hepatotoxicity: another cause of the vanishing bile duct syndrome","volume":"102","author":"Forbes","year":"1992","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2021.10.011_bib68","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1002\/hep.1840200610","article-title":"Chlorpromazine-induced vanishing bile duct syndrome leading to biliary cirrhosis","volume":"20","author":"Moradpour","year":"1994","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2021.10.011_bib69","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/S0168-8278(05)80476-3","article-title":"Antibiotic-associated acute vanishing bile duct syndrome: a pattern associated with severe, prolonged, intrahepatic cholestasis","volume":"20","author":"Davies","year":"1994","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.10.011_bib70","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/j.1600-0676.1993.tb00635.x","article-title":"A\u00a0case of drug-induced ductopenia resulting in fatal biliary cirrhosis","volume":"13","author":"Ishii","year":"1993","journal-title":"Liver"},{"key":"10.1016\/j.jhep.2021.10.011_bib71","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1097\/00042737-200209000-00014","article-title":"Reversible vanishing bile duct syndrome induced by carbamazepine","volume":"14","author":"Ramos","year":"2002","journal-title":"Eur J Gastroenterol"},{"key":"10.1016\/j.jhep.2021.10.011_bib72","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1097\/01.pas.0000213342.78475.48","article-title":"Restoration of bile ducts in drug-induced vanishing bile duct syndrome due to zonisamide","volume":"30","author":"Vuppalanchi","year":"2006","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.jhep.2021.10.011_bib73","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1002\/hep.28967","article-title":"Clinical presentation and outcomes of bile duct loss caused by drugs and dietary supplements","volume":"65","author":"Bonkovsky","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2021.10.011_bib74","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1159\/000507695","article-title":"Fatal cholestatic liver injury during treatment with PD1 immune checkpoint inhibitor for malignant melanoma","volume":"13","author":"Thorsteinsdottir","year":"2020","journal-title":"Casee Rep Oncol"},{"key":"10.1016\/j.jhep.2021.10.011_bib75","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/0300-2977(94)00058-H","article-title":"Chronic hepatitis caused by lisinopril","volume":"46","author":"Droste","year":"1995","journal-title":"Neth J Med"},{"key":"10.1016\/j.jhep.2021.10.011_bib76","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/S0002-9343(05)80060-9","article-title":"Methotrexate and histologic hepatic abnormalities: a meta-analysis","volume":"90","author":"Whiting-O'Keefe","year":"1991","journal-title":"Am J Med"},{"key":"10.1016\/j.jhep.2021.10.011_bib77","series-title":"Drug-Induced Liver Disease","first-page":"593","article-title":"Hepatotoxicity related to methotrexate","author":"Aithal","year":"2013"},{"key":"10.1016\/j.jhep.2021.10.011_bib78","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1111\/apt.12912","article-title":"End-stage methotrexate-related liver disease is rare and associated with features of the metabolic syndrome","volume":"40","author":"Dawwas","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2021.10.011_bib79","first-page":"369","article-title":"Methotrexate hepatotoxicity in psoriatics: report of 104 patients from Nova Scotia, with analysis of risks from obesity, diabetes and alcohol consumption during long term follow-up","volume":"10","author":"Malatjalian","year":"1996","journal-title":"Can J Gastroenterol"},{"key":"10.1016\/j.jhep.2021.10.011_bib80","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/j.jhep.2007.01.024","article-title":"Psoriasis patients with diabetes type 2 are at high risk of developing liver fibrosis during methotrexate treatment","volume":"46","author":"Rosenberg","year":"2007","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.10.011_bib81","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/S0016-5085(19)32568-5","article-title":"Isoniazid-associated hepatitis in 114 patients","volume":"69","author":"Black","year":"1975","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2021.10.011_bib82","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/S0016-5085(77)80141-8","article-title":"Dantrolene-associated hepatic\u00a0injury. Incidence and character","volume":"72","author":"Utili","year":"1977","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2021.10.011_bib83","doi-asserted-by":"crossref","first-page":"14","DOI":"10.7326\/0003-4819-92-1-14","article-title":"Chronic active hepatitis and severe hepatic necrosis associated with nitrofurantoin","volume":"92","author":"Sharp","year":"1980","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jhep.2021.10.011_bib84","doi-asserted-by":"crossref","first-page":"865","DOI":"10.3109\/00365528109181815","article-title":"Histologic follow-up of alpha-methyldopa-induced liver injury","volume":"16","author":"Arranto","year":"1981","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.jhep.2021.10.011_bib85","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1159\/000198941","article-title":"Chronic hepatitis after successive halothane anesthetics","volume":"27","author":"Kronborg","year":"1983","journal-title":"Digestion"},{"key":"10.1016\/j.jhep.2021.10.011_bib86","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1002\/hep.1840080514","article-title":"Amiodarone-induced hepatic phospholipidosis: a morphological alteration independent of pseudoalcoholic liver disease","volume":"8","author":"Guigui","year":"1988","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2021.10.011_bib87","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1002\/hep.1840090504","article-title":"Amiodarone hepatotoxicity: prevalence and clinicopathologic correlations among 104 patients","volume":"9","author":"Lewis","year":"1989","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2021.10.011_bib88","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/j.1742-1241.1989.tb08690.x","article-title":"Chronic active hepatitis associated with diclofenac sodium therapy","volume":"43","author":"Mazeika","year":"1989","journal-title":"Br J Clin Pract"},{"key":"10.1016\/j.jhep.2021.10.011_bib89","doi-asserted-by":"crossref","first-page":"223","DOI":"10.3109\/00313029309066576","article-title":"Flucloxacillin induced liver disease: histopathological findings at biopsy and autopsy","volume":"25","author":"Eckstein","year":"1993","journal-title":"Pathology"},{"issue":"8-9","key":"10.1016\/j.jhep.2021.10.011_bib90","first-page":"612","article-title":"[Chronic active cirrhogenic hepatitis induced by fenofibrate]","volume":"17","author":"Chatrenet","year":"1993","journal-title":"Gastroenterol Clin Biol"},{"key":"10.1016\/j.jhep.2021.10.011_bib91","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0168-8278(99)80362-6","article-title":"Rapid progression to liver cirrhosis of toxic hepatitis due to ebrotidine","volume":"31","author":"Pineda","year":"1999","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.10.011_bib92","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/PL00001983","article-title":"Acute liver failure due to enalapril","volume":"25","author":"Jeserich","year":"2000","journal-title":"Herz"},{"key":"10.1016\/j.jhep.2021.10.011_bib93","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/S0002-9343(02)01109-9","article-title":"Terbinafine hepatotoxicity resulting in chronic biliary-ductopenia and portal fibrosis","volume":"112","author":"Anania","year":"2002","journal-title":"Am J Med"},{"key":"10.1016\/j.jhep.2021.10.011_bib94","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.5858\/2003-127-1493-RH","article-title":"Ramipril-associated hepatotoxicity","volume":"127","author":"Yeung","year":"2003","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.jhep.2021.10.011_bib95","first-page":"235","article-title":"[Liver cirrhosis due to chronic use of nitrofurantoin]","volume":"148","author":"Volbeda","year":"2004","journal-title":"Ned Tijdschr Geneeskd"},{"key":"10.1016\/j.jhep.2021.10.011_bib96","doi-asserted-by":"crossref","first-page":"5394","DOI":"10.3748\/wjg.v11.i34.5394","article-title":"Liver\u00a0cirrhosis induced by long-term administration of a daily low\u00a0dose\u00a0of amiodarone: a case report","volume":"11","author":"Oikawa","year":"2005","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jhep.2021.10.011_bib97","first-page":"444","article-title":"Myelotoxicity and hepatotoxicity during azathioprine therapy","volume":"63","author":"de Boer","year":"2005","journal-title":"Neth J Med"},{"key":"10.1016\/j.jhep.2021.10.011_bib98","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1002\/hep.28323","article-title":"Categorization of drugs implicated in causing liver injury: critical assessment based upon published case reports","volume":"63","author":"Bj\u00f6rnsson","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2021.10.011_bib99","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1053\/j.gastro.2013.02.006","article-title":"Incidence, presentation and outcomes in patients with drug-induced liver injury in the general population of Iceland","volume":"144","author":"Bj\u00f6rnsson","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2021.10.011_bib100","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1177\/106002809502900605","article-title":"Fatal hepatotoxicity following oral administration of amiodarone","volume":"29","author":"Richer","year":"1995","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.jhep.2021.10.011_bib101","series-title":"Drug-induced liver injury","first-page":"135","article-title":"Liver sinusoidal endothelial cells and liver injury","year":"2013"},{"issue":"1","key":"10.1016\/j.jhep.2021.10.011_bib102","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.cld.2019.09.004","article-title":"Liver histology: diagnostic and prognostic features","volume":"24","author":"Gasmi","year":"2020","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.jhep.2021.10.011_bib103","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1055\/s-2002-23204","article-title":"Toxic injury to hepatic sinusoids: sinusoidal obstruction syndrome (veno-occlusive disease)","volume":"22","author":"DeLeve","year":"2002","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.jhep.2021.10.011_bib104","series-title":"Drug-induced liver injury","first-page":"630","article-title":"Hepatotoxicity of herbal and dietary supplements","author":"Seff","year":"2013"},{"key":"10.1016\/j.jhep.2021.10.011_bib105","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.jhep.2010.12.003","article-title":"Herbal medicine hepatotoxicity: a new step with development of specific biomarkers","volume":"54","author":"Larrey","year":"2011","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.10.011_bib106","doi-asserted-by":"crossref","first-page":"158","DOI":"10.7326\/0003-4819-90-2-158","article-title":"Veno-occlusive disease of the liver after allogeneic bone marrow transplantation: possible association with graft-versus-host disease","volume":"90","author":"Berk","year":"1979","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jhep.2021.10.011_bib107","doi-asserted-by":"crossref","first-page":"589","DOI":"10.4065\/78.5.589","article-title":"Hepatic veno-occlusive disease (sinusoidal obstruction syndrome) after hematopoietic stem cell transplantation","volume":"78","author":"Kumar","year":"2003","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.jhep.2021.10.011_bib108","series-title":"Clinical and Research Information on Drug-Induced Liver Injury","year":"2012"},{"key":"10.1016\/j.jhep.2021.10.011_bib109","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1365-2036.2006.02742.x","article-title":"Review article: updates in the pathogenesis and therapy of hepatic sinusoidal obstruction syndrome","volume":"23","author":"Helmy","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2021.10.011_bib110","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1093\/annonc\/mdh095","article-title":"Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer","volume":"15","author":"Rubbia-Brandt","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jhep.2021.10.011_bib111","series-title":"Clinical and Research Information on Drug-Induced Liver Injury","year":"2012"},{"key":"10.1016\/j.jhep.2021.10.011_bib112","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1097\/SLA.0b013e3181c79403","article-title":"Predicting high grade lesions of sinusoidal obstruction syndrome related to oxaliplatin-based chemotherapy for colorectal liver metastases: correlation with post-hepatectomy outcome","volume":"251","author":"Soubrane","year":"2010","journal-title":"Ann Surg"},{"key":"10.1016\/j.jhep.2021.10.011_bib113","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1200\/JCO.2009.27.5701","article-title":"Oxaliplatin-mediated increase in spleen size as a biomarker for the development of hepatic sinusoidal injury","volume":"28","author":"Overman","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jhep.2021.10.011_bib114","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1097\/SLA.0b013e31815774de","article-title":"Sinusoidal injury increases morbidity after major hepatectomy in patients with colorectal liver metastases receiving preoperative chemotherapy","volume":"247","author":"Nakano","year":"2008","journal-title":"Ann Surg"},{"key":"10.1016\/j.jhep.2021.10.011_bib115","first-page":"225","article-title":"Portal hypertension associated with oxaliplatin administration: clinical manifestations of hepatic sinusoidal injury","volume":"8","author":"Slade","year":"2009","journal-title":"Clin Colorectal Cancer"},{"issue":"1123","key":"10.1016\/j.jhep.2021.10.011_bib116","doi-asserted-by":"crossref","first-page":"20210352","DOI":"10.1259\/bjr.20210352","article-title":"Long-term follow-up of oxaliplatin-induced liver damage in patients with colorectal cancer","volume":"94","author":"Cha","year":"2021","journal-title":"Br J Radiol"},{"key":"10.1016\/j.jhep.2021.10.011_bib117","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.ejso.2008.12.013","article-title":"Bevacizumab protects against sinusoidal obstruction syndrome and does not increase response rate in neoadjuvant XELOX\/FOLFOX therapy of colorectal cancer liver metastases","volume":"35","author":"Klinger","year":"2009","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.jhep.2021.10.011_bib118","doi-asserted-by":"crossref","first-page":"152882","DOI":"10.1016\/j.tox.2021.152882","article-title":"Oxaliplatin-induced hepatic sinusoidal obstruction syndrome","author":"Zhu","year":"2021","journal-title":"Toxicology"},{"key":"10.1016\/j.jhep.2021.10.011_bib119","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/s41572-019-0105-0","article-title":"Drug-induced liver injury","volume":"5","author":"Andrade","year":"2019","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.jhep.2021.10.011_bib120","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/MAJ.0b013e3181e15da8","article-title":"Hepatotoxicity fears contribute to underutilization of statin medications by primary care physicians","volume":"340","author":"Rzouq","year":"2010","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.jhep.2021.10.011_bib121","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1007\/BF03262001","article-title":"Internet accounts of serious adverse drug reactions: a study of experiences of Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"35","author":"Butt","year":"2012","journal-title":"Drug Saf"},{"key":"10.1016\/j.jhep.2021.10.011_bib122","doi-asserted-by":"crossref","first-page":"9069","DOI":"10.3748\/wjg.v19.i47.9069","article-title":"Anxiety and depression propensities in patients with acute toxic liver injury","volume":"19","author":"Suh","year":"2013","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jhep.2021.10.011_bib123","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1002\/lt.23688","article-title":"Quality of life is significantly impaired in long-term survivors of acute liver failure and particularly in acetaminophen-overdose patients","volume":"19","author":"Rangnekar","year":"2013","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhep.2021.10.011_bib124","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","article-title":"The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection","volume":"30","author":"Ware","year":"1992","journal-title":"Med Care"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827821021188?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827821021188?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T19:43:16Z","timestamp":1759174996000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827821021188"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":124,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["S0168827821021188"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2021.10.011","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term sequelae of drug-induced liver injury","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2021.10.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}